Stryker announces $662M Entellus acquisition: 4 insights

Written by Mackenzie Garrity | December 07, 2017 | Print  |

Stryker reached an agreement to acquire Entellus Medical, a developer of ENT products, for $662 million.

Here are four insights:


1. Entellus Medical designs various ear, nose and throat products for minimally invasive treatments. The company's portfolio includes XprESS Multi-Sinus Dilation System and the Latera Absorbable Nasal Implant.


2. The closing of the transaction is subject to approval by Entellus' stockholders and is expected to be dilute to Stryker's 2018 adjusted net earnings by approximately $0.04 and accretive thereafter.


3. Guggenheim Securities served as the financial advisor for Stryker with Skadden, Arps, Slate, Meagher & Flom serving as outside legal counsel.


4. Robert White, CEO of Entellus, said, "The combination of Stryker's established commitment to making healthcare better and Entellus' innovative products with the ENT segment will continue to provide our customers the tools they need for cost effective solutions."


More articles on devices and implants:
WishBone Medical appoints Jean-Pierre Capdevielle chief strategy officer: 3 notes
Smith & Nephew acquire Rotation Medical for $210M: 4 key points
FDA releases new guidance for 3-D printing medical devices: 5 things to know

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months